Shares of Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating, one has given a buy rating and four have assigned a strong buy rating to the company.
A number of equities analysts recently weighed in on GLX shares. ATB Cormark Capital Markets downgraded shares of Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a report on Thursday, February 5th. Citigroup upgraded shares of Bradmer Pharmaceuticals to a “hold” rating in a report on Tuesday, February 24th. Finally, Chardan Capital upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, May 4th.
Check Out Our Latest Stock Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
